Logo

BMS Reports Three and Five-Year Data of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III (CheckMate -9LA) and (CheckMate -227) Trial for mNSCLC

Share this
BMS Reports Three and Five-Year Data of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III (CheckMate -9LA) and (CheckMate -227) Trial for mNSCLC

BMS Reports Three and Five-Year Data of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III (CheckMate -9LA) and (CheckMate -227) Trial for mNSCLC

Shots:

  • The 3yr. results from the P-III (CheckMate -9LA) trial evaluating Opdivo + Yervoy & CT vs CT alone & 5 yr. results from part 1 of the P-III (CheckMate -227) trial of Opdivo + Yervoy vs CT for mNSCLC
  • In both trials, the results showed OS benefits at a minimum follow-up of 3 or 5yrs., OS rate (25% & 24% vs 15% & 14%) in patients with tumor PD-L1 expression <1% & ≥1%; patients were alive (27% & 19% vs 19% & 7%). In (CheckMate -9LA) trial, OS benefit & durable clinical benefit were observed in an exploratory analysis & OS rate (24% vs 11%) in sq. histology
  • In PD-L1 ≥1% & <1% in (CheckMate -227) trial, patients responded (28% & 21% vs 3% & 0%); alive (66% & 64%). The safety profile was consistent with prior reported data with no new safety signals

Ref: BMS | Image: BMS

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions